All‐cause long‐term mortality: range 4 to 6 months · adults with cardiogenic shock or low cardiac output syndrome
It is very uncertain whether levosimendan changes all‐cause long‐term mortality: range 4 to 6 months compared with placebo (very low certainty).
1 finding from 1 review
All‐cause short‐term mortality: 30 days · adults with cardiogenic shock
It is very uncertain whether levosimendan changes all‐cause short‐term mortality: 30 days compared with enoximone (very low certainty).
1 finding from 1 review
All‐cause long‐term mortality · adults with cardiogenic shock
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause short‐term mortality: 28 days · adults with cardiogenic shock
It is very uncertain whether epinephrine changes all‐cause short‐term mortality: 28 days compared with norepinephrine‐dobutamine (very low certainty).
1 finding from 1 review
All‐cause long‐term mortality · adults with cardiogenic shock
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause short‐term mortality: time in hospital · adults with low cardiac output syndrome
It is very uncertain whether dopexamine changes all‐cause short‐term mortality: time in hospital compared with dopamine (very low certainty).
1 finding from 1 review
Intervention not reported
PIPP score (difference between baseline and heel lance period) · Neonates
1 finding from 1 review
Intervention not reported
Duration of crying (seconds) during the first 3 minutes · Neonates
1 finding from 1 review
Intervention not reported
PIPP (maximum score within 3 minutes following lancing) · Neonates
1 finding from 1 review
Intervention not reported
PIPP score in first 45 seconds of eye examination · Neonates
1 finding from 1 review
Intervention not reported
PIPP score 5 minutes after eye examination · Neonates
1 finding from 1 review
Intervention not reported
Lung function Mean percentage change in FEV1 · adults and children with cystic fibrosis
1 finding from 1 review
Intervention not reported
Lung function Mean percentage change in FVC (% predicted) · adults and children with cystic fibrosis
1 finding from 1 review
Intervention not reported
Nutritional status BMI · adults and children with cystic fibrosis
1 finding from 1 review
Intervention not reported
Time to first exacerbation requiring intravenous antibiotics · adults and children with cystic fibrosis
1 finding from 1 review
Intervention not reported
Antibiotic resistance patterns following treatment · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Ototoxicity An increase in auditory threshold of 20 dB or more over any frequency range · adults and children with cystic fibrosis
The intervention showed no clear difference in ototoxicity An increase in auditory threshold of 20 dB or more over… (low certainty).
1 finding from 1 review
Intervention not reported
Nephrotoxicity The percentage change in creatinine over baseline · adults and children with cystic fibrosis
1 finding from 1 review
Referral for thoracic surgery (open or thorascopic) · adult parapneumonic effusions and empyema
Alteplase showed no clear difference in referral for thoracic surgery (open or thorascopic) compared with urokinase (low certainty).
1 finding from 1 review
Serious adverse events · adult parapneumonic effusions and empyema
Alteplase may leads to higher serious adverse events compared with urokinase (low certainty).
1 finding from 1 review